Low Doses of Aspirin in the Prevention of Preeclampsia (ASAPP)
Preeclampsia
About this trial
This is an interventional prevention trial for Preeclampsia focused on measuring Preterm preeclampsia, Preeclampsia with severe features, High risk pregnancy, Low dose aspirin, Cell free RNA, Compliance
Eligibility Criteria
Patients are currently only being enrolled at the New York Presbyterian Weill Cornell Medicine and at the New York Presbyterian Queens campuses.
Inclusion Criteria:
Pregnant patients, ≥18 years old, at less than 16 weeks' gestation (as documented by ultrasound) with at least one of the following risk factors for developing PE:
- PE in a prior pregnancy
- Chronic hypertension (prior to pregnancy or before 20 weeks' gestation)
- Type 1 or 2 diabetes
- Renal disease (proteinuria ≥300mg/day or estimated GFR<90mL/min/1.73 m2)
- Multifetal gestation
- Autoimmune disease (e.g. systemic lupus erythematous, antiphospholipid syndrome)
Exclusion Criteria:
- Patient with known intention to terminate pregnancy
- Major fetal malformation seen on ultrasound
- Contraindication to ASA therapy (including but not limited to allergy and high bleeding risk)
Sites / Locations
- New York Presbyterian - Weill Cornell
- New York Presbyterian Queens
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
81mg ASA
162mg ASA
Patients in Arm 1, will be instructed to take one tablet of 81mg aspirin per day.
Patients in Arm 2, will be instructed to take two tablets simultaneously orally once per day.